This FcγRIIb-mediated internalization of rituximab was correlated with receptor expression in different subtypes of B cell lymphoma, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma, follicular lymphoma (FL), and diffuse large B cell lymphoma [96,97]. The gene discussed is FCGR2B; the disease is B-cell non-Hodgkin lymphoma.